Literature DB >> 16513864

Prognostic variables at intake and long-term level of function in schizophrenia.

Steven J Siegel1, Farzin Irani, Colleen M Brensinger, Christian G Kohler, Warren B Bilker, J Daniel Ragland, Stephen J Kanes, Ruben C Gur, Raquel E Gur.   

Abstract

OBJECTIVE: This study assessed the relationship between symptoms and cognitive measures at intake and functional outcome 2-8 years later (average 3 years) in first-episode and previously treated schizophrenia patients.
METHOD: A composite cognitive score was assessed at intake to determine the influence of cognition on later functional outcome. At intake and follow-up, positive and negative symptoms were assessed with the Scale for the Assessment of Positive Symptoms and the Scale for the Assessment of Negative Symptoms, and affective symptoms were assessed with the Hamilton Depression Rating Scale. Level of function in seven domains (social function, occupational function, independent living, symptom severity, fullness of life, extent of psychiatric hospitalization, and overall level of function) at intake and follow-up was assessed with the Strauss-Carpenter Level of Function scale. The contributions of sex, education, and duration of illness to functional outcome were also examined.
RESULTS: The results indicated that symptoms at intake had distinct patterns of prognostic significance for functional outcome in previously treated patients, compared with first-episode patients. In addition, male and female patients differed in the degree to which initial symptoms were correlated with later function.
CONCLUSIONS: Initial level of function, symptoms, sex, education, and duration of illness are all important predictors for functional outcome in patients with schizophrenia.

Entities:  

Mesh:

Year:  2006        PMID: 16513864     DOI: 10.1176/appi.ajp.163.3.433

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  28 in total

Review 1.  Gamma synchrony: towards a translational biomarker for the treatment-resistant symptoms of schizophrenia.

Authors:  Michael J Gandal; J Christopher Edgar; Kerstin Klook; Steven J Siegel
Journal:  Neuropharmacology       Date:  2011-02-22       Impact factor: 5.250

2.  The Portuguese version of the Personal and Social Performance Scale (PSP): reliability, validity, and relationship with cognitive measures in hospitalized and community schizophrenia patients.

Authors:  Sofia Brissos; Filipa Palhavã; João Gama Marques; Susana Mexia; Ana Lisa Carmo; Manuel Carvalho; Cátia Dias; João Data Franco; Rita Mendes; Pedro Zuzarte; Ana Isabel Carita; Andrew Molodynski; Maria Luisa Figueira
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2011-07-08       Impact factor: 4.328

3.  Empowerment and its associations in schizophrenia: a cross-sectional study.

Authors:  Amlan Kusum Jana; Daya Ram; Samir Kumar Praharaj
Journal:  Community Ment Health J       Date:  2014-05-03

4.  Symptomatic Remission in Schizophrenia and its Relationship with Functional Outcome Measures in Indian Population.

Authors:  Selvaraj Madhivanan; Komal Jayaraman; Sharon Joe Daniel; Jeyaprakash Ramasamy
Journal:  J Clin Diagn Res       Date:  2017-01-01

5.  A meta-analysis of emotion perception and functional outcomes in schizophrenia.

Authors:  Farzin Irani; Sarah Seligman; Vidyulata Kamath; Christian Kohler; Ruben C Gur
Journal:  Schizophr Res       Date:  2012-02-15       Impact factor: 4.939

6.  Neuropsychological performance in older patients with schizophrenia: a meta-analysis of cross-sectional and longitudinal studies.

Authors:  Farzin Irani; Solomon Kalkstein; Emily A Moberg; Paul J Moberg
Journal:  Schizophr Bull       Date:  2010-06-14       Impact factor: 9.306

7.  Parvalbumin cell ablation of NMDA-R1 causes increased resting network excitability with associated social and self-care deficits.

Authors:  Eddie N Billingslea; Valerie M Tatard-Leitman; Jaynie Anguiano; Catherine R Jutzeler; Jimmy Suh; John A Saunders; Susumu Morita; Robert E Featherstone; Pavel I Ortinski; Michael J Gandal; Robert Lin; Yuling Liang; Raquel E Gur; Gregory C Carlson; Chang-Gyu Hahn; Steven J Siegel
Journal:  Neuropsychopharmacology       Date:  2014-02-14       Impact factor: 7.853

8.  Negative symptoms and functioning during the first year after a recent onset of schizophrenia and 8 years later.

Authors:  Joseph Ventura; Kenneth L Subotnik; Michael J Gitlin; Denise Gretchen-Doorly; Arielle Ered; Kathleen F Villa; Gerhard S Hellemann; Keith H Nuechterlein
Journal:  Schizophr Res       Date:  2014-12-08       Impact factor: 4.939

9.  Functioning in middle aged and older patients with schizophrenia and depressive symptoms: relationship to psychopathology.

Authors:  John Kasckow; Thomas Patterson; Ian Fellows; Shahrokh Golshan; Ellen Solorzano; Somaia Mohamed; Sidney Zisook
Journal:  Am J Geriatr Psychiatry       Date:  2008-08       Impact factor: 4.105

10.  Source-based morphometry of gray matter volume in men with first-episode schizophrenia.

Authors:  Tomás Kaspárek; Radek Marecek; Daniel Schwarz; Radovan Prikryl; Jirí Vanícek; Michal Mikl; Eva Cesková
Journal:  Hum Brain Mapp       Date:  2010-02       Impact factor: 5.038

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.